

# Victoria K Woodcock

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1271988/publications.pdf>

Version: 2024-02-01

11  
papers

955  
citations

1306789

7  
h-index

1473754

9  
g-index

12  
all docs

12  
docs citations

12  
times ranked

2723  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19. JAMA Network Open, 2022, 5, e220130.	2.8	34
2	Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. Clinical Cancer Research, 2020, 26, 5869-5878.	3.2	131
3	COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncology, The, 2020, 21, 1309-1316.	5.1	473
4	Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma. Nature Medicine, 2020, 26, 193-199.	15.2	211
5	Variability in body temperature in healthy adults and in patients receiving chemotherapy: prospective observational cohort study. Journal of Medical Engineering and Technology, 2019, 43, 323-333.	0.8	4
6	First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity. European Journal of Cancer, 2019, 109, 103-110.	1.3	76
7	Testicular cancer in men with undescended testis: Insights from the Thames Valley Testicular Cancer database. Journal of Clinical Urology, 2019, 12, 274-279.	0.1	0
8	A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC).. Journal of Clinical Oncology, 2019, 37, 406-406.	0.8	8
9	A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. British Journal of Cancer, 2018, 118, 770-776.	2.9	9
10	Results of a Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CXD101: Preliminary Safety and Activity in Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma Patients. Blood, 2016, 128, 1817-1817.	0.6	1
11	Simultaneous bilateral spontaneous hydropneumothorax: a rare presentation of bilateral malignant pleural mesothelioma. BMJ Case Reports, 2013, 2013, bcr2013009350-bcr2013009350.	0.2	6